The increasing complexity of today’s novel compounds make drug development more challenging than ever. To be able to meet the growing needs of patients around the world, a company must have a strategy that can shepherd new biologic therapies throughout the development timeline.
If, in the course of the development process, undesirable effects occur that negatively impact API scale-up, it can prevent a company from delivering a product with reliable quality and efficacy. For these reasons, a company must be aware of any potential conditions that could occur at a small-scale that could create major issues during commercial scale-up.
Implementing a bioavailability enhancing formulation approach can positively impact safety, efficacy, and patient adherence, leading to successful clinical outcomes. An in-depth look at how lipid-based drug delivery systems (LBDDS) with softgel dosage form can be used as a bioavailability enhancing technology for successful clinical outcomes.
A Q&A session with formulation and bioavailability experts on addressing formulation challenges for pediatric populations.
The road to take a drug compound from discovery to commercialization is long, expensive and often fraught with unforeseen challenges. While every project will undoubtedly face some bumps along its path, far too many programs hit insurmountable obstacles that require innovators to backtrack and correct their course before proceeding, further extending timelines and adding costs.
Zydis® fast dissolve formulation for Zelapar® (Selegiline anti-Parkinson’s compound) had a positive impact on the patient compliance as compared to the Selegiline traditional tablets.
While the wider use of opioids has led to many benefits for patients in pain, it also has led to higher incidences of misuse, abuse, and development of opioid addiction. To address this issue without preventing legitimate patients from receiving their necessary medication, Grünenthal set out to create an abuse-deterrent formulation with a technology that creates a physico-chemical barrier to abuse and, as a result, safeguards patients from the battle of addiction.
Pharmaceutical ointments are engineered to have rheological properties important to the physical performance of the product when used by the consumer.
Moisturizing creams will be defined by their viscosity or thickness. Formulating moisturizing creams depends on the required end product consistency, influencing the choice of material to use.
Anton Paar's Generation M density meters and Abbemat refractometers deliver accurate and repeatable measurement results while providing system security for 21 CFR Part 11 compliance.